Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Conformational Landscape of N-Glycosylated Peptides Detecting Autoantibodies in Multiple Sclerosis, Revealed by Hamiltonian Replica Exchange.
Laminin-411 Is a Vascular Ligand for MCAM and Facilitates TH17 Cell Entry into the CNS.
lipid-specific IgM bands in csf associated with a reduced risk of developing pml during treatment with natalizumab.
Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
Molecular properties of epithelial, amiloride-blockable Na+ channels.
Materials for stem cell factories of the future.
Self-perceived performance and satisfaction with performance of daily activities in persons with multiple sclerosis following interdisciplinary rehabilitation.
Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment.
Multiple sclerosis.
Exploring the CLEC16A gene reveals a MS-associated variant with correlation to the relative expression of CLEC16A isoforms in thymus.
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study.
[A comparison analysis of the use of intravenous β-interferon-1a 30 mcg and subcutaneous β-interferon-1a 44 mcg in routine clinical practice of treatment in patients with multiple sclerosis].
Evaluating more naturalistic outcome measures: A 1-year smartphone study in multiple sclerosis.
Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial.
Tumefactive multiple sclerosis lesions under fingolimod treatment.
Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Inhibition of glycerophosphate-dependent H2O2 generation in brown fat mitochondria by idebenone.
Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis.
Validation of a Dutch version of the Neurological Fatigue Index (NFI-MS) for patients with multiple sclerosis in the Netherlands.
Health Canada Approves PLEGRIDY™ (peginterferon beta-1a) for Adults with Relapsing Remitting Multiple Sclerosis
Periventricular lesions help differentiate neuromyelitis optica spectrum disorders from multiple sclerosis.
The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
Treatment of walking impairment in multiple sclerosis with dalfampridine.
Gilenya prescribing information

Pages